Clover Biopharma

Clover Biopharmaceuticals is a global clinical-stage biotechnology company focused on developing novel vaccines and biologic therapeutic candidates. The company's core technology is the proprietary Trimer-Tag platform, which allows for the production of trimeric fusion proteins that mimic the natural structure of viral and human proteins. Their lead product, SCB-2019 (CpG 1018/Alum), is a protein-based COVID-19 vaccine that has received emergency use authorization in several countries. Beyond COVID-19, Clover is advancing a pipeline targeting respiratory syncytial virus (RSV), influenza, and various oncology and autoimmune indications. The company maintains integrated capabilities across R&D, clinical development, and large-scale GMP manufacturing.